General Information

A New Phase III Trial of ODM-201 for Men with Castrate Resistant Prostate Cancer without Visible Metastases

Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company) have announced that they have begun enrollment in a randomized Phase III clinical trial of a new investigational treatment for men with advanced prostate cancer. ODM-201 is a novel, oral androgen receptor inhibitor. The trial named ARAMIS trial is a randomized, Phase III, multi-center, double-blind, placebo-controlled [...]

By |2021-02-17T11:03:15-05:00September 21st, 2014|Advanced Prostate Cancer, Androgan Receptor Inhibitor, Drugs & Treatments, General Information, Hormone Therapy, OMD-201, Uncategorized|1 Comment
Read More

Chemo-Brain and ADT for Advanced Prostate Cancer – Does It Exist?

When I went on my first round of hormone therapy (ADT) I experienced severe cognitive side effects. I found it impossible to concentrate, read and remember anything. I lost the ability to navigate the New York City subways no less drive my car to a destination. Occasionally, when I was attempting to navigate the subway [...]

By |2017-10-19T10:48:02-04:00September 15th, 2014|ADT, Advanced Prostate Cancer, General Information, Hormone Therapy, Me, Quality of Life, Research, Uncategorized, Understanding APC|5 Comments
Read More

Xtandi (enzaludamide) Receives FDA Approval in the Pre-Chemo Stage of Prostate Cancer Treatment

Expected and extraordinary news today on the new treatment front. Medivation and Astellas’ Xtandi (enzalutamide) was approved for use in men with castrate resistant prostate cancer. The new FDA approved label for Xtandi says that it is for the treatment of men with metastatic castration-resistant prostate cancer. This label is basically the same as for [...]

By |2014-09-10T17:03:53-04:00September 10th, 2014|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, enzalutamide, General Information, survival, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments
Read More

Thank You My Readers for Your Support in Being Awarded the Harry Pinchot Service Award

I recently was informed that I am to honored with the 2014 Harry Pinchot Award from the Prostate Cancer Research Institute.  The award recognizes outstanding dedication and support to the prostate cancer community. I am pleased and flattered to be one of this year's receptients.I have been told that one reason I have received this [...]

By |2017-10-19T10:48:04-04:00August 26th, 2014|Advanced Prostate Cancer, General Information, Uncategorized|9 Comments
Read More

Incidence of advanced prostate cancer in men under the age of 50 in the United States: A population-based study 1973-2010

Clouded in the murkiness of the debate surrounding the use of the PSA test is an increasing escalation of younger men (under the age of 50 years) being diagnosed with advanced prostate cancer. We know that there has been escalating incidence rate (IR) of prostate cancer PC noted in the last two decades. Many have [...]

By |2017-10-19T10:48:05-04:00August 19th, 2014|Advanced Prostate Cancer, General Information, Uncategorized, Understanding APC|0 Comments
Read More

Study Shows That The Immune Responses Is Enhanced and Sustained When Provenge Is Given After Androgen Deprivation Therapy in Biochemically-Recurrent Prostate Cancer

Last April there was some preliminary data from the long-term Phase II STAND study presented at 29th Annual European Association of Urology (EAU) Congress that showed that sipuleucel-T (Provenge) when given after the start of androgen deprivation therapy (ADT) seemed to enhance and sustain the immune response in men with a biochemical failure (PSA only) [...]

By |2017-10-19T10:48:06-04:00August 12th, 2014|ADT, Advanced Prostate Cancer, Bio Chemical Recurrence, Drugs & Treatments, General Information, Provenge, survival, Uncategorized, Understanding APC|2 Comments
Read More

Join Me in Los Angeles in September at the PCRI Prostate Cancer Patient Conference

There are conferences for doctors and conferences for researchers, but there is also a conference just for prostate cancer survivors and their caretakers! The Prostate Cancer Research Institute (PCRI), a partner of Malecare, annually sponsors the only patient conference in the world. I have attended the conference over the last five years and strongly recommend [...]

By |2021-04-29T10:07:31-04:00July 28th, 2014|Advanced Prostate Cancer, General Information, Uncategorized|4 Comments
Read More

Predicting Resistance to Enzalutamide and Abiraterone in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC).*

In yesterday's post I wrote about the possibility of looking for the presence of the splice variant ARV7 to determine if you would be resistant to enzalutamide (Xtandi).  Today I am going to expand on this issue and discuss an additional study that demonstrated that the presence of ARV7 in circulating tumor cells not only [...]

By |2017-10-19T10:48:07-04:00July 16th, 2014|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Drugs & Treatments, enzalutamide, General Information, ipilimumab, Research, Uncategorized, Understanding APC, Xtandi, Zytiga|0 Comments
Read More

Anticoagulants May Increase Survival in Men with Advanced Prostate Cancer Taking Chemotherapy*

Over the past two to three years there have been some small studies that have indicated that the use of concomitant anticoagulants along with docetaxel (chemotherapy) may improve overall survival The most recent examination of this issue was performed by a team led by Emmanuel S. Antonarakis, MD, of Johns Hopkins University in Baltimore.  They [...]

By |2020-02-04T11:48:55-05:00July 11th, 2014|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, General Information, Research, survival, Uncategorized, Understanding APC|0 Comments
Read More
Go to Top